Odonate Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Odonate Therapeutics, Inc.
Keen On NASDAQ Slot, Concentra Looks To Scupper Jounce And Redx Merger
In February, Jounce’s future looked bleak after the failure of vopratelimab and fears that its finances would run out. Now, it has two suitors with Concentra making a bid to compete with an all-stock merger with the UK’s Redx.
Finance Watch: One Small Pain Drug Maker And Three Biotech SPACs Launch IPOs
After a brief lull in US initial public offerings, PainReform and three special purpose acquisition companies kicked off September’s IPOs. Also, Immunovant offering grossed $173.9m, Carlyle Group bought 5% stake in China’s Salubris and Erasca increased its series B to $236m.
Odonate's Oral Taxane Tesetaxel Shows PFS Benefit In Metastatic Breast Cancer Phase III
The convenient oral therapy could have benefits over more traditional infused taxane chemotherapies, and a new drug application filing is planned for 2021.
Fennec Nears Market For Chemo-Induced Hearing Loss in Children
Cisplatin is very effective but two thirds of children treated with the drug for cancer are left with some hearing loss. If approved this year, Fennec's Pedmark could go some way to preventing that distressing side effect.
- Other Names / Subsidiaries
- Odonate Therapeutics, LLC
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.